Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment

Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR‐TKI tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Haixia, Yu, Shaorong, Chen, Dan, Jing, Changwen, Wang, Zhuo, Ma, Rong, Liu, Siwen, Ni, Jie, Feng, Jifeng, Wu, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221460/
https://www.ncbi.nlm.nih.gov/pubmed/28097086
http://dx.doi.org/10.1002/2211-5463.12147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221460/
https://www.ncbi.nlm.nih.gov/pubmed/28097086
http://dx.doi.org/10.1002/2211-5463.12147

Ejemplares similares